Capstone Therapeutics Corp (CAPS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1275 WEST WASHINGTON STREET TEMPE, AZ 85281 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2019 MRQ | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,341 | 1,275 | 698 | 1,011 | 2,164 | 6,258 | |||
| Cash and cash equivalents | 1,341 | 1,275 | 698 | 1,011 | 2,164 | 6,258 | |||
| Other current assets | 97 | 98 | 131 | 247 | 555 | 233 | |||
| Total current assets: | 1,438 | 1,373 | 829 | 1,258 | 2,719 | 6,491 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 3 | ||||||||
| Long-term investments and receivables | 6,000 | 6,000 | |||||||
| Long-term investments | 6,000 | 6,000 | |||||||
| Intangible assets, net (including goodwill) | 39 | 196 | 353 | 509 | 666 | 823 | |||
| Intangible assets, net (excluding goodwill) | 39 | 196 | 353 | 509 | 666 | 823 | |||
| Other undisclosed noncurrent assets | (6,000) | (6,000) | |||||||
| Total noncurrent assets: | 39 | 196 | 353 | 509 | 666 | 826 | |||
| TOTAL ASSETS: | 1,477 | 1,569 | 1,182 | 1,767 | 3,385 | 7,317 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 246 | 199 | 304 | 261 | 282 | 100 | |||
| Accounts payable | 245 | 197 | 249 | 254 | 124 | 88 | |||
| Accrued liabilities | 1 | 2 | 55 | 7 | 158 | 12 | |||
| Total current liabilities: | 246 | 199 | 304 | 261 | 282 | 100 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 2,475 | 2,249 | 1,000 | 1,000 | |||||
| Long-term debt, excluding current maturities | 2,475 | 2,249 | 1,000 | 1,000 | |||||
| Total noncurrent liabilities: | 2,475 | 2,249 | 1,000 | 1,000 | |||||
| Total liabilities: | 2,721 | 2,448 | 1,304 | 1,261 | 282 | 100 | |||
| Equity | |||||||||
| Equity, attributable to parent | (1,244) | (879) | (122) | 506 | 3,103 | 7,217 | |||
| Common stock | 27 | 27 | 20 | 20 | 20 | 20 | |||
| Additional paid in capital | 190,483 | 190,468 | 189,477 | 189,442 | 189,268 | 189,215 | |||
| Accumulated deficit | (191,754) | (191,374) | (189,619) | (188,956) | (186,185) | (182,018) | |||
| Total equity: | (1,244) | (879) | (122) | 506 | 3,103 | 7,217 | |||
| TOTAL LIABILITIES AND EQUITY: | 1,477 | 1,569 | 1,182 | 1,767 | 3,385 | 7,317 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | (2,000) | |||||||
| Gross profit: | (2,000) | |||||||
| Operating expenses | (2,181) | (1,680) | (1,584) | (2,939) | (4,524) | (4,293) | ||
| Other undisclosed operating income | 4,362 | |||||||
| Operating income (loss): | 181 | (1,680) | (1,584) | (2,939) | (4,524) | (4,293) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 251 | (111) | (81) | (24) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 432 | (1,791) | (1,665) | (2,963) | (4,524) | (4,293) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (43) | 158 | ||||||
| Income (loss) from continuing operations before income taxes: | 432 | (1,791) | (1,665) | (2,963) | (4,567) | (4,135) | ||
| Income tax expense (benefit) | (52) | 36 | 56 | 192 | 400 | 21 | ||
| Income (loss) from continuing operations: | 380 | (1,755) | (1,609) | (2,771) | (4,167) | (4,114) | ||
| Income (loss) before gain (loss) on sale of properties: | 380 | (1,755) | (1,609) | (2,771) | (4,167) | (4,114) | ||
| Net income (loss): | 380 | (1,755) | (1,609) | (2,771) | (4,167) | (4,114) | ||
| Net income attributable to noncontrolling interest | 946 | 193 | ||||||
| Net income (loss) available to common stockholders, diluted: | 380 | (1,755) | (663) | (2,771) | (4,167) | (3,921) | ||
Comprehensive Income ($ in thousands)
| 6/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 380 | (1,755) | (1,609) | (2,771) | (4,167) | (4,114) | ||
| Comprehensive income (loss): | 380 | (1,755) | (1,609) | (2,771) | (4,167) | (4,114) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 946 | (193) | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 380 | (1,755) | (663) | (2,771) | (4,167) | (4,307) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.